wow, we are headed for the moonz
Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15. This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart. IMHO, it appears to be in technical and fractal alignment. Weekly chart...
ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19. And the Market Cap is only...
ARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2. Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil. Before Aridis, Bill & Melinda Gates Foundation...
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal...
Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19. Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials. My price target is...
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon! Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...
Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
New Data suggest COVAXIN (BBV152) may provide protection against current and future variants! data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant. 52 Week Range 0.28 - 18.77 My price target is the 10.30usd resistance.
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200 CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants KEY POINTS: - Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants. - The companies announced...
If you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend &...
NRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant. Information was released by Israel Institute for Biological Research. Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines. I consider this a premium call, the upside i see here is 400%, or the 24usd...
Not financial advice! We can clearly see the ascending channel of this stock. Even though the stock is running for quite some time now, I don't think it will actually stop before we see $54,XX. After last earnings the stock gained about 20% and reached the top of channel after 14 trading days. From my point of view, since the last earnings reported were even...
European Commission’s independent experts selected Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19! CEO of Humanigen said today: "We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19". In the...
After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher! Get ready for action! My first price target is 35usd. Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure! NRx Pharmaceuticals has also a Partnership...
On 6/11/2021 Piper Sandler brokerage Initiated Coverage giving a price target of $18.00 VXRT Vaxart today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. (prnewswire.com) This is in...